Angiotensin converting enzyme inhibitors and calcium antagonists are effective agents for controlling high blood pressure in diabetic patients. We selected 30 type II diabetic patients with proteinuria and evaluated the effect of these drugs on renal function and proteinuria. In a double-blind trial, patients received either 40 ing/day enalapril or 40 mg/day nifedipine during 12 months. They also received a hypoproteic diet with 0.8 g/kg wt/day of protein. In the enalapril group (10 men and eight women), mean arterial blood pressure was 112.0±12 mm Hg, creatinine clearance was 58.6±12.4 ml/min, and 24-hour proteinuria was 4J6±3.23 g/24 hr before treatment After treatment, mean arterial blood pressure was 82.0±8 JO mm Hg (p<0.001), creatinine clearance was 66.6±13.8 ml/min (NS), and 24-hour proteinuria was 0.56±0.78 g/24 hr (p<0.001). In the nifedipine group (six men and six women), mean arterial blood pressure was 114.0±8.0 mm Hg, creatinine clearance was 67.8±19.6 ml/min, and 24-hour proteinuria was 2.84±131 g/24 hr before treatment After treatment, mean arterial blood pressure was 86.0±7.0 mm Hg (/?<0.001), creatinine clearance was 51.4±7.9 ml/min (p<0.001), and 24-hour proteinuria was 2.66±0.89 g/24 hr (NS). These results show a similar hypotensive action and different renal effects between these two drugs after 12 months of treatment (Hypertension 1992;19[suppl U]:n-237-U-242) H ypertension develops in half or more of all diabetic patients, and diabetes is twofold or threefold more commonly found in hypertensive than in normotensive individuals.
H ypertension develops in half or more of all diabetic patients, and diabetes is twofold or threefold more commonly found in hypertensive than in normotensive individuals. 1 " 3 We evaluated the effects of two antihypertensive agents, enalapril and nifedipine, on renal function and proteinuria of 30 hypertensive diabetic patients.
Methods
We studied 30 hypertensive type II diabetic patients (16 men and 14 women) with clinical diabetic nephropathy. Hypertension had an evolution of at least 10 years in all patients. Proteinuria in all cases was >1 g/24 hr. All patients gave informed consent before starting the trial.
Basal studies were done three times in a period of 45 days before treatment was started. In a doubleblind trial, patients received either 40 mg/day enalapril (20 mg twice a day) or regular 40 mg/day nifedipine (10 mg four times a day) for 12 months. They also were given a hypoproteic diet with 0.8 g/kg wt/day of protein.
Basal and posttreatment values of creatinine clearance, potassium levels, and proteinuria are the average of three successive measurements. Two weeks were allowed between basal and posttreatment measurements.
We evaluated the effects of enalapril and nifedipine on renal function, proteinuria, and blood pressure. Patients were clinically evaluated monthly, and laboratory assessment was done every 3 months. Data were compared and statistical analyses were performed using the Student's t or Z test according to the number of patients we were evaluating. Table 1 shows general results for the 30 patients. Enalapril caused significant changes in real endogenous creatinine, protein excretion (24-hour proteinuria), and creatinine clearance in both groups after 12 months of treatment.
Results
In the enalapril group, serum potassium level before treatment was 3.8±1.1 meq/1 and after treatment was 5.0±0.4 meq/1. In the nifedipine group, serum potassium level before treatment was 4.1 ±0.8 meq/1 and after treatment was 3.8±1.3 meq/1.
Both drugs showed a similar hypotensive action and different renal effects after treatment (see Table  1 for general results). Individual results are shown in Tables 2-5 . Figures 1-4 show the evolution of creatinine clearance and 24-hour proteinuria with enal- In diabetic patients, mortality is increased because of cardiovascular diseases similar to those observed in hypertensive patients, as shown in the Framingham study. Another important cause of mortality in insulin-dependent diabetes mellitus is renal failure. Hypertension accelerates renal damage and increases morbidity from diabetic nephropathy. 10 -28 Beyond the special considerations regarding protection against diabetic nephropathy, antihypertensive therapy is now being widely used to treat hypertension in diabetic patients. If early antihypertensive therapy proves to be effective in preventing the development of cardiovascular diseases (as is now being actively studied), its application will be still greater.
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Calcium Antagonists
Calcium antagonists may cause glomerular filtration rate and renal blood flow to increase. A transient natriuresis usually accompanies the use of these drugs. They do not activate the renin-aldosterone mechanism. 29 . 30 Regarding their effects on carbohydrate metabolism, except for a few reports about a diabetogenic effect of nifedipine, a fairly extensive body of experimental and clinical data indicates that none of the calcium antagonists interferes with insulin or any other hormone release, as well as with plasma glucose or insulin levels in diabetic and in nondiabetic patients.
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Angiotensin Converting Enzyme Inhibitors
Despite the small number of patients studied, our results are encouraging. Angiotensin converting enzyme (ACE) inhibition might be able to control Regarding their use in diabetic patients, ACE inhibitors might provide specific protection against glomerular sclerosis in addition to a good antihypertensive action with little if any effect on carbohydrate or lipid metabolism. A few reports have documented hypoglycemia and increased insulin sensitivity after administration of both captopril and enalapril, but a quick recovery from this insulin-induced hypoglycemia has been observed in nondiabetic hypertensive patients.
Specific protection against glomerular sclerosis has been observed in experimental animals with diabetes as well as in animals with renal insufficiency when treated with ACE inhibitors. But this effect was not present when standard triple therapy or calcium antagonists were administered despite equal lowering of blood pressure in all cases. When renal insufficiency was present, a reduction in glomerular capillary blood pressure was observed, whereas glomerular plasma flow rate was not reduced. This maintenance of flow at lower pressure would tend to preserve renal function and reduce progressive sclerosis of glomerular capillaries caused by intraglomerular hypertension. 31 -36 The apparent advantage of ACE inhibitors over other antihypertensive agents has been attributed to their specific ability to reduce efferent arteriolar resistance, thereby reducing glomerular capillary hydraulic pressure. In addition to this rather striking experimental evidence, therapy with ACE inhibitors has been shown to reduce both proteinuria and the fall of glomerular filtration rate in hypertensive diabetic patients. These clinical effects should not occur only with ACE inhibitors, because similar effects have been observed with other antihypertensive agents. But we must consider the possibility that other antihypertensive agents may further increase glomerular pressure if they also dilate renal afferent arterioles through a direct action or as a result of the reduction of systemic blood pressure. 30 showed that, when using diltiazem in diabetic patients, a reduction in proteinuria occurred similar to that observed when lisinopril was administered, whereas creatinine clearance showed no significant changes with both drugs. The same authors demonstrated in another trial that, when renal effects of diltiazem and nifedipine in diabetic patients were compared, the first drug caused proteinuria to decrease, with no changes in creatinine clearance, and the second one decreased creatinine clearance and increased proteinuria.
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This latter result does not differ from what we observed in our patients. Although a small decrease in proteinuria was shown by the end of the trial, it was not a significant one.
Conclusion
In conclusion, similar antihypertensive effects were achieved with enalapril and nifedipine, and their action on renal function was significantly different after 12 months of treatment.
Reduction of blood pressure probably is not responsible for decreasing proteinuria in diabetic patients. The patients in our study achieved normal blood pressure levels with both enalapril and nifedipine, but the effect of these drugs on urinary protein excretion was different. The decrease in proteinuria would not be due to changes in glomerular filtration rate either, because with the use of enalapril, a reduction in proteinuria occurs while glomerular filtration rate remains unchanged. Because the cardiovascular risks associated with hypertension superimposed on diabetes may be additive, and because blood pressure reduction slows the progression of diabetic nephropathy, early and aggressive intervention is mandatory in hypertensive diabetic patients. We recommend that ACE inhibitors be used as first-line antihypertensive agents in the treatment of hypertensive diabetic patients.
